C-Rad AB (FRA:24C) ROCE %: 13.42% (As of Mar. 2026)

What is C-Rad AB ROCE %?

C-Rad AB FRA:24C -1.78% 89 ROCE % is 13.42% as of Mar. 2026. GuruFocus rates FRA:24C with a GF Score™ of 89/100 and a GF Value™ of €2.86 (Modestly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. C-Rad AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 13.42%.

C-Rad AB (FRA:24C) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

C-Rad AB ROCE % Related Terms

C-Rad AB ROCE % Historical Data

* Premium members only.

The historical data trend for C-Rad AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C-Rad AB ROCE % Chart

C-Rad AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

16.08

8.75

16.91

25.94

4.95

C-Rad AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															12.17	9.71	23.71	5.98	13.42

89GF Score

C-Rad AB FRA:24C

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

C-Rad AB ROCE % Calculation

C-Rad AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	1.541	/	( ( (42.544 - 13.273)	+	(46.019 - 13.027) )	/ 2 )
	=	1.541	/	( (29.271	+	32.992)	/ 2 )
	=	1.541	/	31.1315
	=	4.95 %

C-Rad AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	4.456	/	( ( (46.019 - 13.027)	+	(46.438 - 13.035) )	/ 2 )
	=	4.456	/	( ( 32.992	+	33.403 )	/ 2 )
	=	4.456	/	33.1975
	=	13.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 13.42% mean?

C-Rad AB (FRA:24C) has a ROCE % of 13.42% as of Mar. 2026.

Is C-Rad AB's ROCE % too high?

C-Rad AB's current ROCE % is 13.42%. The Medical Devices & Instruments industry median ROCE % is 2.23. C-Rad AB's value of 13.42% is 501.8% above this industry median. Overall, C-Rad AB has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does C-Rad AB's ROCE % compare to ABT and SYK?

C-Rad AB's ROCE % of 13.42% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. C-Rad AB's value of 13.42% is 501.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current ROCE % of 13.42% is 501.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current ROCE % is 13.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is C-Rad AB stock overvalued right now?

Based on GuruFocus' analysis, C-Rad AB (FRA:24C) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.86, compared to a current price of €3.32 — trading 16.1% above its estimated fair value. The current ROCE % is 13.42% and 501.8% above the Medical Devices & Instruments industry median of 2.23. C-Rad AB's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For C-Rad AB (FRA:24C), the current ROCE % is 13.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C-Rad AB (FRA:24C) Overvalued in 2026?

Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued. The current stock price of €3.32 is trading 16.1% above its estimated GF Value™ of €2.86. GuruFocus considers C-Rad AB to be Modestly Overvalued.

Key valuation signals for FRA:24C:

ROCE %: 13.42%
GF Value™: €2.86 vs. price of €3.32 (16.1% above fair value)
GF Score™: 89/100 with 4 warning signs
Industry Position: 501.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the FRA:24C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C-Rad AB Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OSTO:PAX OSTO:BICO OSTO:SEDANA OSTO:EPIS B OSTO:SEZI OSTO:DVYSR OSTO:BACTI B OSTO:SCIB OSTO:OSSD OSTO:MNTC ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges CRAD B:Sweden 0R44:UK

Address Sjukhusvagen 12K, Uppsala, SWE, 753 09

Website https://www.c-rad.com

C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.

89GF Score

Get the complete analysis for FRA:24C

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32

Price

€2.86

GF Value

View FRA:24C Analysis

See ROCE % data for all stocks →